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Abstract
This letter considers the main challenges that people with rare diseases and their families face: delay in diagnosis,
lack of appropriate support and information, and impaired access to treatment. The differences in medical experience
between a patient with a rare disease and one with a common one are made through the use of a real-life example:
the diagnosis of leiomyosarcoma received by my mother. I highlight how patients with rare disease are often
misdiagnoses and how their symptoms are often overlooked. I also highlight the isolation patients with rare
diseases and their families experience due to the lack of knowledge about their condition, the struggle to access
treatment and the small amount of information and evidence based medicine for managing rare conditions.
This article was the winning entry in the Findacure essay contest ‘The Student Voice’. More information about
Findacure can be found at http://www.findacure.org.uk.
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“Unfortunately it is cancer. It is called undifferentiated
pleomorphic uterine sarcoma, but the doctors are not
sure, it could be a leiomyosarcoma. They have never
seen a similar case before.”
I remember the day my father called me to give me
the terrible news. I could not believe that it was my own
mother affected by a disease with such a frightening
name. Remembering the spelling so I could Google it
was hard enough. I was only at the end of my first year
of medical school and thought it was normal that I had
never heard of it. I soon realised that it was too rare to
be covered in lectures. In the few hours after my father’s
call I discovered that uterine sarcomas account for 1 %
of uterine cancers [1], and uterine cancer in turn makes
up only 2.5 % of cancer diagnoses [2]. I could not find a
specific incidence rate for her cancer, because no one
was ever sure of the diagnosis. Suddenly, I realised that
the challenges my family was going to face to receive ap-
propriate care were greater than the ones we would have
faced had this cancer been more common.
A rare disease is defined by the European Union as a
“disease that affects less than 5 in 10,000 people” [3].
There are between 6000 and 8000 rare diseases [3]. Col-
lectively, they are common: in the UK 1 in 17 people will
be affected by a rare disease at some point in their life
[3]. Rare diseases are heterogeneous: they can result
from a single gene mutation, often inherited, or from a
combination of environmental and genetic factors.
In this essay I consider the main challenges that
people with rare diseases and their families face: delays
in diagnosis, lack of appropriate support and informa-
tion, and impaired access to treatment.
“I have to send you to A&E. This bleeding is not
normal, it could be a warning sign of something
serious.”
My mother was lucky in the sense that her cancer
presented with a common alarm symptom: heavy post-
menopausal bleeding. The GP recognised that the
symptoms could be serious and she was immediately
referred to secondary care. In a week she had a diagno-
sis and a plan to access appropriate treatment. Many
people with rare diseases present with “odd” symptoms
and experience long delays before the correct diagnosis
is made. A survey from Rare Diseases UK from 2010Correspondence: roberta.garau.12@aberdeen.ac.uk
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reports that only 26 % of respondents had a diagnosis
in less than 3 months, 46 % had to wait more than one
year [4]. Some rare diseases are similar to common
ones, causing multiple misdiagnoses. An alarming 30 %
of patients who answered the survey received three or
more misdiagnoses. The survey reports the story of Jo
Gray, a woman affected by multiple endocrine neopla-
sia type 2B (MEN-2B) [4]. She had to wait three years
before receiving a diagnosis of MEN-2B. Her mother
and son were subsequently found to also have the con-
dition. The delay in diagnosis put her, and her loved
ones, at serious risk of complications such as heart fail-
ure, stroke and even death [4]. She presented to her GP
with retching, vomiting, severe headache attacks, palpi-
tations and breathlessness [4]. She was a new mother
and was misdiagnosed with postnatal depression [4].
MEN-2 syndromes are extremely rare conditions,
affecting only around 1000 families worldwide [5]. It is
understandable that the first differential diagnosis in
her GP’s list was not a MEN syndrome; postnatal de-
pression is a common diagnosis and probably a correct
one for most new mothers with similar symptoms.
However, the inability to listen to Mrs. Gray’s concerns,
to see her desperation, to acknowledge the failure of
treatments for her diagnosis was inexcusable. These
shortcomings are a threat to a positive medical experi-
ence for rare and common diseases alike. In both cases,
there is a risk of forgetting the person behind the symp-
toms. The focus should never move from the patients’
experience to the doctor’s idea of how a disease should
progress and how a patient should behave to fit in.
“I have never done an operation for this kind of
tumour. The specialist is in Milan, he would be
technically more proficient but it could be a long wait.
You have to decide what to do.”
On the broad spectrum of cancer patients, my mother
was fortunate in that her tumour was at least operable.
However, her treatment journey is a microcosm of the
battle people with rare diseases face. The gynaecologist
in my city was brutally honest in stating that he had no
experience carrying out the required operation. The best
person to do so was 430 miles away in Milan, and we
would have to wait a month before he became available.
The other option was to opt for immediate surgery
locally. But how does one weigh up the value of a sur-
geon with experience of a rare cancer against the risk of
giving a rapidly proliferating cancer an extra month to
grow? I will never know if we made the right decision by
opting to wait and travel to Milan. If we had chosen to
act immediately perhaps my mother’s metastases would
have come earlier, later, or not at all. Unfortunately that
is the world in which sufferers of rare diseases and their
families must live - a world of hypotheticals. No evi-
dence exists to direct patient or clinician down a par-
ticular path.
My entire family was desperate to know everything
they could about my mother’s cancer to make the best
decisions. Unfortunately, all we were given by way of an
explanation at the local hospital was that it was a very
rare, aggressive disease. The internet became the main
source of information: websites targeted at people with
sarcomas became our main support. Reading about
others’ experiences, learning about treatments and
promising research broke our isolation and empowered
us. Even if only through the internet, my mother was
able to relate her experience with that of someone else
with the same condition, in the same way as people with
hypertension talk about their medication while waiting
to see the doctor. Technology is available for any patient,
irrespective of the incidence of their condition. It is a
double-edged sword: it can provide good quality, evi-
dence based information and totally unreliable, even
dangerous information. For patients like my mother, the
line between good and bad is hard to draw. Technology
should never replace good information and support from
trained healthcare professionals.
“Clinical trials have insufficient numbers of patients to
draw meaningful conclusions”
I remember looking up the Italian guidelines on leio-
myosarcoma management. I had just spent weeks learn-
ing the Scottish equivalents for common diseases for my
exams: management of an acute MI, therapy adjustment
for asthma. I naively expected the same level of detail
for my mother’s disease. The guidelines can be broadly
paraphrased as: “We do not know which chemotherapy
works best for uterine sarcomas. Here are a list of drugs
you should try in any order.” Given the paucity of evi-
dence and recommendations, I could not blame the
oncologist for his reticence to initiate chemotherapy.
Equally, I do not blame him for being unaware of the
existence of the final chemotherapy agent she received.
After all, when my father found about this drug, he
agreed to read up on it. He was of further assistance
when it became apparent that this drug was not immedi-
ately available for people like my mother on the Italian
national health service. He made enquiries and arranged
its delivery to the local hospital, although the process
took three months. Three months my mum did not
have.
My mother’s chemotherapy battle highlights a strange
paradox only glimpsed by people with rare diseases - pa-
tients and their families are often more knowledgeable
than the professionals. Doctors are unaware of poten-
tially effective treatments simply because they have
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never had cause to use them before, or because the
drugs are not licensed for a rare disease.
If I developed a rare disease…
If I develop a rare condition at the same age my
mother was diagnosed, it would be the year 2050. I hope
that by then, a family with a relative affected by a rare
condition will not have to envy those of people affected
by common conditions. I hope that guidelines will be
published by professional bodies for a greater number of
rare diseases. I hope there will be more multi-centred,
multi-national randomised controlled trials and greater
resources for treatment, both in terms of drugs and
skilled professionals. I hope they will be readily access-
ible temporally and geographically. Most of all, I hope
that nobody ever feels that same sense of fear I felt the
first time I realised my mother’s cancer was rare.
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